LKPC(SH:600789) Ge Long Hui A P P·2025-12-26 09:28Group 1 - Company Shandong Lukang Pharmaceutical Group Saiter Co., Ltd. received a drug registration certificate for Finasteride tablets from the National Medical Products Administration, indicating approval as a generic drug that meets quality and efficacy consistency evaluation [1] - Finasteride is a synthetic steroid compound that acts as a specific inhibitor of the enzyme 5α-reductase type II, which converts testosterone to dihydrotestosterone (DHT), playing a significant role in benign prostatic hyperplasia (BPH) [1] - The 1mg specification of Finasteride is indicated for the treatment of male pattern baldness, promoting hair growth and preventing further hair loss, while the 5mg specification is used for treating and controlling BPH, improving urinary flow and related symptoms [1] Group 2 - There are currently 46 production approvals for Finasteride tablets in China, with 24 companies holding 29 approvals that have passed or are deemed to have passed the quality and efficacy consistency evaluation [2] - The total sales of Finasteride tablets in hospitals across China for the years 2022, 2023, 2024, and the first half of 2025 are approximately CNY 469 million, CNY 483 million, CNY 490 million, and CNY 343 million respectively [2] - Since the start of research and development, Saiter Company has invested approximately CNY 3.5 million in R&D (unaudited) [2]